Author/Authors :
Fakharian Atefeh نويسنده , Jamaati Hamidreza نويسنده Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran , Kharabian Masouleh Shahram نويسنده Shahid Beheshti University of Medical Sciences, Chronic
Respiratory Diseases Research Center, Tehran, IR Iran , Karimzadeh Saba نويسنده Shahid Beheshti University of Medical Sciences, Chronic
Respiratory Diseases Research Center, Tehran, IR Iran
Abstract :
Background Noninvasive positive-pressure ventilation (NIPPV) has
been safely used in selected patient populations. The purpose of this
study was to determine the safety and efficacy of NIPPV outside the
intensive care unit (ICU) in a tertiary hospital. This descriptive,
cross sectional study was performed at Masih Daneshvari Hospital,
Tehran, Iran during 2011 - 2015. Methods Between March 2011 and June
2015, patients requiring NIPPV were enrolled in the study. The study
population included all eligible patients. Census sampling was applied
in this study. The patients’ medical history (including comorbidities),
age, sex, and hospital ward in which NIPPV was delivered were assessed
retrospectively. Moreover, venous pH, partial pressure of carbon dioxide
(PCO2), and bicarbonate
(HCO3-) were analyzed before and after the
intervention (NIPPV application). Results A total of 946 patients,
including 598 (63.2%) men and 348 (36.8%) women, received NIPPV for
inpatient hospital care. The mean age of the patients was 61.92 ± 15.5
years (range, 3 - 102 years). Indications for NIPPV included
exacerbation of chronic obstructive pulmonary disease (COPD; 55.4%),
obstructive sleep apnea (OSA; 6%), bronchiectasis (7.8%), concurrence of
COPD and OSA (4.8%), neuromuscular disorders (1.7%), congestive heart
failure (4%), postthoracotomy pain (0.6%), thoracic malignancy (2.1%),
pulmonary thromboembolism (1.1%), pneumonia (7.3%), asthma (1.5%),
interstitial lung disease (2.5%), tuberculosis (4%), and cystic fibrosis
(1.3%). We found significant improvements in venous pH and PCO2 with no
significant changes in HCO3- (P > 0.05).
Conclusions NIPPV could be safely used under the supervision of trained
pulmonologists in non-ICU settings. This method was effective in
treating acute abnormalities in venous blood gas, including pH and
PCO2.